Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive ...

Geneva-based Neurosterix’s lead drug candidate is a selective muscarinic M4 positive allosteric modulator (PAM) with potential as a treatment for schizophrenia, and it will also work on a ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...